We previously demonstrated that B16-F10 melanoma cells, which are resistant to anti-PD-1 therapy in vivo, exhibit relatively low expression of CCL5 and CXCL10, two key chemokines essential for recruiting NK and CD8+ T cells to the tumor microenvironment. The gene discussed is CCL5; the disease is neoplasm.